Biomarkers for predicting prostate cancer progression
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsMark A. Rubin, Francesca DeMichelis
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification and use of gene expression profiles with clinical relevance to prostate cancer. In particular, the invention provides the identity of genes whose expression, at the transcriptional and protein levels, is correlated with prostate cancer progression. Methods and kits are described for using these gene expression profiles in the study and/or diagnosis of prostate cancer diseases, in the prediction of prostate cancer progression, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that target these genes or their protein products, in particular for the development of therapeutics for modulating prostate cancer progression.
Claims32
A kit for diagnosing prostate disease in a subject, said kit comprising:
- a set of reagents that specifically detects expression levels of a set of genes comprising ABP280 (FLNA) and at least three or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52;
- and
- instructions for using said kit for diagnosing prostate disease in the subject.
A kit for providing a prognosis for prostate disease in a subject, said kit comprising:
- a set of reagents that specifically detects expression levels of a set of genes comprising ABP280 (FLNA) and at least three or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52;
- and
- instructions for using said kit for providing a prognosis for prostate disease in the subject.
Dependencies are inferred from the claim text.